Ataxia Telangiectasia (AT) is a rare autosomal recessive neurodegenerative disorder characterized by progressive [cerebellar[/brain-regions/[cerebellum[/brain-regions/[cerebellum[/brain-regions/[cerebellum[/brain-regions/[cerebellum--TEMP--/brain-regions)--FIX-- ataxia, immunodeficiency, and increased cancer susceptibility[1][4]. This page provides comprehensive information about the disease, including its genetics, pathophysiology, clinical features, diagnosis, and current treatment approaches.
Ataxia Telangiectasia is a rare inherited disorder that affects multiple systems of the body, particularly the nervous system, immune system, and other organs[1]. The disease is characterized by:
- Progressive [cerebellar[/brain-regions/[cerebellum[/brain-regions/[cerebellum[/brain-regions/[cerebellum[/brain-regions/[cerebellum--TEMP--/brain-regions)--FIX-- ataxia: Loss of coordination and balance due to degeneration of the [cerebellum[/brain-regions/[cerebellum[/brain-regions/[cerebellum[/brain-regions/[cerebellum[/brain-regions/[cerebellum--TEMP--/brain-regions)--FIX--[1]
- Telangiectasias: Dilated blood vessels in the eyes and skin[5]
- Immunodeficiency: Increased susceptibility to infections[1]
- Cancer predisposition: Significantly elevated risk of leukemia and lymphomas[4][8]
AT is caused by mutations in the ATM (Ataxia-Telangiectasia Mutated) gene, which encodes a protein essential for [DNA repair[/mechanisms/[dna-repair[/mechanisms/[dna-repair[/mechanisms/[dna-repair[/mechanisms/[dna-repair--TEMP--/mechanisms)--FIX--, cell cycle control, and cellular response to [oxidative stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress--TEMP--/mechanisms)--FIX--[2][3]. The disease typically presents in early childhood, with most patients requiring wheelchair assistance by adolescence[4].
¶ Genetics and Molecular Basis
The ATM gene, located on chromosome 11q22-23, encodes the ATM protein kinase, a key regulator of the cellular response to [DNA double-strand breaks[/mechanisms/[dna-repair[/mechanisms/[dna-repair[/mechanisms/[dna-repair[/mechanisms/[dna-repair--TEMP--/mechanisms)--FIX--[6][7]. Over 700 pathogenic variants have been identified in the ATM gene, including:
- Nonsense mutations: Premature stop codons leading to truncated proteins[2]
- Missense mutations: Amino acid substitutions affecting protein function[2]
- Splice site mutations: Abnormal processing of ATM mRNA[2]
- Large deletions: Complete or partial gene deletions[2]
Approximately 1-2% of the population are carriers of an ATM mutation, with carrier frequency varying by ethnicity[4]. Carriers have a moderately increased risk of breast cancer, cardiovascular disease, and insulin resistance[4][9].
The ATM protein plays critical roles in:
- [DNA repair[/mechanisms/[dna-repair[/mechanisms/[dna-repair[/mechanisms/[dna-repair[/mechanisms/[dna-repair--TEMP--/mechanisms)--FIX--: ATM activates the DNA damage response cascade, phosphorylating key proteins including p53, BRCA1, and checkpoint kinases (Chk1/Chk2) to facilitate [DNA repair[/mechanisms/[dna-repair[/mechanisms/[dna-repair[/mechanisms/[dna-repair[/mechanisms/[dna-repair--TEMP--/mechanisms)--FIX--[2][8]
- Cell Cycle Control: ATM helps maintain genomic stability by coordinating cell cycle arrest in response to DNA damage[2][8]
- [Mitochondrial function[/mechanisms/[mitochondrial-dysfunction-ad[/mechanisms/[mitochondrial-dysfunction-ad[/mechanisms/[mitochondrial-dysfunction-ad[/mechanisms/[mitochondrial-dysfunction-ad--TEMP--/mechanisms)--FIX--: ATM deficiency leads to mitochondrial dysfunction/mitochondrial-dysfunction)-dysfunction) and increased [oxidative stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress--TEMP--/mechanisms)--FIX--[9]
- Vascular Development: Abnormal telangiectasia formation is linked to defective vascular development[1][5]
[cerebellar[/brain-regions/[cerebellum[/brain-regions/[cerebellum[/brain-regions/[cerebellum[/brain-regions/[cerebellum--TEMP--/brain-regions)--FIX-- degeneration in AT primarily affects Purkinje cells and granule cells, leading to progressive ataxia[1][4]. The [cerebellum[/brain-regions/[cerebellum[/brain-regions/[cerebellum[/brain-regions/[cerebellum[/brain-regions/[cerebellum--TEMP--/brain-regions)--FIX-- plays a crucial role in coordinating voluntary movements, and its degeneration results in the characteristic unsteady gait and loss of motor control[1].
- [cerebellar[/brain-regions/[cerebellum[/brain-regions/[cerebellum[/brain-regions/[cerebellum[/brain-regions/[cerebellum--TEMP--/brain-regions)--FIX-- Ataxia: Progressive loss of coordination, beginning with difficulty walking and evolving to complete loss of ambulation[1][4]
- Dysarthria: Slurred speech due to impaired coordination of facial muscles[1]
- Dysphagia: Difficulty swallowing[1]
- Oculomotor Apraxia: Abnormal eye movements, particularly difficulty with voluntary gaze shifting[4]
- Peripheral Neuropathy: Loss of sensation and reflexes in extremities[4]
- Myoclonus: Involuntary muscle jerks[4]
- Cognitive Impairment: Variable intellectual disability in some patients[4]
- Telangiectasias: Dilated blood vessels appearing on the conjunctiva (eyes) and facial skin, typically developing between ages 3-5[5]
- Immunodeficiency: Reduced levels of IgA, IgE, and IgG, leading to recurrent sinopulmonary infections[1][4]
- Elevated Alpha-Fetoprotein (AFP): A characteristic biomarker, elevated in nearly all AT patients[4]
- Growth Retardation: Poor growth velocity and short stature[4]
- Delayed Puberty: Hormonal deficiencies affecting sexual development[4]
- Endocrine Abnormalities: Diabetes mellitus, hypothyroidism, and gonadal failure[4]
- Radiation Sensitivity: Extreme sensitivity to ionizing radiation due to [DNA repair[/mechanisms/[dna-repair[/mechanisms/[dna-repair[/mechanisms/[dna-repair[/mechanisms/[dna-repair--TEMP--/mechanisms)--FIX-- defect[1][8]
AT patients have a 100-fold increased risk of lymphoid malignancies, particularly[8][9]:
- Acute lymphoblastic leukemia (ALL)
- Acute myeloid leukemia (AML)
- Non-Hodgkin lymphoma
Carriers of ATM mutations also have a modestly increased risk of breast cancer, pancreatic cancer, and cardiovascular disease[4][9].
Diagnosis is based on a combination of[1][4]:
- Progressive [cerebellar[/brain-regions/[cerebellum[/brain-regions/[cerebellum[/brain-regions/[cerebellum[/brain-regions/[cerebellum--TEMP--/brain-regions)--FIX-- ataxia presenting in early childhood
- Presence of telangiectasias (typically after age 3)
- Immunodeficiency with recurrent infections
- Elevated serum alpha-fetoprotein (AFP) after age 2
- Family history (autosomal recessive inheritance)
- Genetic Testing: Identification of pathogenic ATM mutations via sequencing[4]
- Biochemical Testing: Reduced or absent ATM protein kinase activity[2]
- Elevated AFP: Serum alpha-fetoprotein elevation is a key diagnostic marker[4]
- Immunodeficiency: Low IgA, IgE, and sometimes IgG levels[1]
- Radiation Sensitivity Testing: Cell culture demonstrating enhanced radiation-induced chromosome breakage[8]
- MRI: [cerebellar[/brain-regions/[cerebellum[/brain-regions/[cerebellum[/brain-regions/[cerebellum[/brain-regions/[cerebellum--TEMP--/brain-regions)--FIX-- atrophy, particularly of the vermis, is characteristic[4]
- CT: May show vermian atrophy in advanced disease[4]
There is no cure for AT. Management focuses on[10]:
-
Symptomatic Treatment:
- Physical therapy to maintain mobility and prevent contractures
- Occupational therapy for daily living skills
- Speech therapy for dysarthria
- Management of swallowing difficulties to prevent aspiration
-
Immunodeficiency Management:
- Antibiotic prophylaxis for respiratory infections
- IVIG (intravenous immunoglobulin) replacement therapy
- Aggressive treatment of infections
-
Cancer Surveillance:
- Regular monitoring for hematological malignancies
- Early intervention when cancers are detected
-
Supportive Care:
- Nutritional support for dysphagia
- Diabetes management
- Cardiac monitoring
Several promising approaches are under investigation[4][10]:
- Gene Therapy: Viral vector delivery of functional ATM gene to restore protein expression
- ATM Kinase Activators: Small molecules to enhance residual ATM function in patients with missense mutations
- Antioxidant Therapy: To address increased [oxidative stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress--TEMP--/mechanisms)--FIX-- in AT cells
- MTOR Inhibitors: Everolimus has shown some benefit in clinical trials
- Bone Marrow Transplantation: For patients with severe immunodeficiency
The prognosis for AT patients has improved with modern medical care, but life expectancy remains significantly reduced[4][10]:
- Median Survival: 20-25 years with comprehensive care
- Primary Causes of Death: Respiratory infections, malignancies, and complications from progressive neurological decline
- Ambulatory Status: Most patients require wheelchair assistance by their early teens
- Cognitive Function: Intelligence is typically preserved, though some patients develop learning disabilities
Several animal models have been developed to study AT[2]:
- ATM-/- Mice: Recapitulate many features of AT including neurodegeneration, immunodeficiency, and cancer predisposition
- Conditional Knockout Models: Allow tissue-specific deletion of ATM to study specific aspects of the disease
- Zebrafish Models: Used for high-throughput drug screening
These models have been instrumental in understanding disease mechanisms and testing potential therapies.
Current research focuses on[4]:
- Gene Therapy: Developing safe and effective viral vectors for ATM delivery
- Pharmacological Chaperones: Small molecules to stabilize mutant ATM proteins
- Stem Cell Therapy: Replacing damaged [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- with stem cell-derived cells
- Biomarker Development: Identifying biomarkers for disease progression and treatment response
- Clinical Trials: Testing novel therapeutic agents in AT patients
- [Spinocerebellar Ataxia Type 17 (SCA17)[/diseases/[spinocerebellar-ataxia-type-17[/diseases/[spinocerebellar-ataxia-type-17[/diseases/[spinocerebellar-ataxia-type-17[/diseases/[spinocerebellar-ataxia-type-17--TEMP--/diseases)--FIX--
- [Friedreich Ataxia[/diseases/[friedreich-ataxia[/diseases/[friedreich-ataxia[/diseases/[friedreich-ataxia[/diseases/[friedreich-ataxia--TEMP--/diseases)--FIX--
- [Spinocerebellar Ataxia Type 6 (SCA6)[/diseases/[spinocerebellar-ataxia-type-6[/diseases/[spinocerebellar-ataxia-type-6[/diseases/[spinocerebellar-ataxia-type-6[/diseases/[spinocerebellar-ataxia-type-6--TEMP--/diseases)--FIX--
- [Fragile X-Associated Tremor/Ataxia Syndrome (FXTAS)[/diseases/[fragile-x-associated-tremor-ataxia-syndrome[/diseases/[fragile-x-associated-tremor-ataxia-syndrome[/diseases/[fragile-x-associated-tremor-ataxia-syndrome[/diseases/[fragile-x-associated-tremor-ataxia-syndrome--TEMP--/diseases)--FIX--
- [Multiple System Atrophy (MSA)[/diseases/[msa[/diseases/[msa[/diseases/[msa[/diseases/[msa--TEMP--/diseases)--FIX--
- [DNA repair mechanisms[/mechanisms/[dna-repair[/mechanisms/[dna-repair[/mechanisms/[dna-repair[/mechanisms/[dna-repair--TEMP--/mechanisms)--FIX--
- [Mitochondrial dysfunction[/mechanisms/[mitochondrial-dysfunction-ad[/mechanisms/[mitochondrial-dysfunction-ad[/mechanisms/[mitochondrial-dysfunction-ad[/mechanisms/[mitochondrial-dysfunction-ad--TEMP--/mechanisms)--FIX--
The study of Ataxia Telangiectasia (At) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
-
Gatti RA, Boder E, Vinters HV, et al. Ataxia-telangiectasia: an interdisciplinary approach to pathogenesis and medicine. Medicine (Baltimore). 1985;64(5):349-366. https://pubmed.ncbi.nlm.nih.gov/4033438/
-
McKinnon PJ. ATM and the molecular pathogenesis of ataxia-telangiectasia. Annu Rev Genomics Hum Genet. 2002;3:247-274. https://pubmed.ncbi.nlm.nih.gov/12142356/
-
Shiloh Y, Ziv Y. The ATM protein: the importance of being active. Nat Rev Cancer. 2013;13(3):173-182. https://pubmed.ncbi.nlm.nih.gov/23385742/
-
Rothblum-Oviatt C, Wright J, Lefton-Greif MA, et al. Ataxia telangiectasia: a review. Orphanet J Rare Dis. 2016;11(1):159. https://pubmed.ncbi.nlm.nih.gov/27881064/
-
Boder E, Sedgwick RP. Ataxia-telangiectasia: a familial syndrome of progressive [cerebellar[/brain-regions/[cerebellum[/brain-regions/[cerebellum[/brain-regions/[cerebellum[/brain-regions/[cerebellum--TEMP--/brain-regions)--FIX-- ataxia, telangiectasia and immunologic deficiency. Trans Am Neurol Assoc. 1958;83:131-137. https://pubmed.ncbi.nlm.nih.gov/13605091/
-
Gatti RA, Berkel I, Boder E, et al. Localization of an ataxia-telangiectasia gene to chromosome 11q22-23. Nature. 1988;336(6199):577-580. https://pubmed.ncbi.nlm.nih.gov/2845388/
-
Ziv Y, Jhanwar SC, Unsal M, et al. The ATM gene and its relevance to human disease. Int J Mol Med. 1999;4(4):357-367. https://pubmed.ncbi.nlm.nih.gov/10517069/
-
Meyn MS. Ataxia-telangiectasia and cellular responses to DNA damage. Cancer Res. 1995;55(24):5991-6001. https://pubmed.ncbi.nlm.nih.gov/8521388/
-
Lavin MF, Kozlov S. ATM: the disease in between. [DNA repair[/mechanisms/[dna-repair[/mechanisms/[dna-repair[/mechanisms/[dna-repair[/mechanisms/[dna-repair--TEMP--/mechanisms)--FIX-- (Amst). 2007;6(5):501-510. https://pubmed.ncbi.nlm.nih.gov/17112767/
-
Perlman SL. Ataxia-telangiectasia. Treat Neurol. 2003;1(4):251-255. https://pubmed.ncbi.nlm.nih.gov/15315533/